Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic adherence to bisphosphonates.

Juraj Payer1, Zdenko Killinger, Ivana Sulková

  • 15th Department of Internal Medicine, Faculty Hospital, Comenius University, Bratislava, Slovakia.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|April 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formyl peptide receptor 1 agonism selectively suppresses mitochondria-driven neutrophil extracellular trap formation while preserving antibacterial immunity.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Neutrophil extracellular traps in the animal model of adenine-induced chronic kidney disease.

PloS one·2026
Same author

Cisplatin - induced peripheral neuropathy and biomarkers of gut microbial translocation in testicular germ cell tumor survivors.

Frontiers in immunology·2026
Same author

Validation of a deep learning model for bone fragility detection from conventional radiographs: an international cohort study.

EClinicalMedicine·2026
Same author

Neonatal testosterone exposure modulates exploration and object avoidance without exacerbating autism-like behavior in Shank3b-deficient mice.

Hormones and behavior·2026
Same author

Ageing, Sex Differences, and REDs Risk in Endurance Runners: An Integrated Cross-Sectional Study Protocol.

Sports (Basel, Switzerland)·2026

Patient adherence to osteoporosis treatment is crucial for success. A once-monthly ibandronate regimen improves patient preference and adherence compared to daily or weekly options.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Patient Adherence Research

Background:

  • Therapeutic adherence significantly impacts treatment outcomes and mortality.
  • Chronic diseases like osteoporosis often suffer from poor patient adherence due to inconvenient treatment regimens.
  • Current bisphosphonate therapies (daily/weekly) present challenges to patient compliance.

Purpose of the Study:

  • To evaluate patient preference for a new once-monthly ibandronate regimen for osteoporosis.
  • To understand the factors influencing therapeutic adherence in osteoporosis management.
  • To compare adherence between different bisphosphonate administration frequencies.

Main Methods:

  • Review of existing studies on therapeutic adherence in clinical practice.

Related Experiment Videos

  • Analysis of questionnaire-based studies assessing patient preference for osteoporosis medications.
  • Comparison of adherence rates associated with different bisphosphonate dosing frequencies (daily, weekly, monthly).

    • Main Results:

    • Patient adherence is a critical, yet often overlooked, factor in treatment efficacy.
    • Osteoporosis management is complicated by the chronic, asymptomatic nature of the disease and patient discomfort with current therapies.
    • Patients strongly prefer the once-monthly ibandronate regimen over once-daily or once-weekly bisphosphonates.

    Conclusions:

    • The frequency of drug application is a key determinant of patient adherence in osteoporosis treatment.
    • The once-monthly ibandronate regimen offers a more comfortable and preferred alternative, potentially improving long-term patient compliance.
    • Further long-term studies are needed to assess the impact of the once-monthly ibandronate regimen on hard clinical endpoints such as mortality.